CD-MEDICS

The overall concept of the CD-MEDICS IP is to develop a technology platform for point-of-care diagnostics, capable of simultaneous genomic and proteomic detection, with embedded communication abilities for direct interfacing with hospital information systems. This will be achieved by exploiting breakthroughs at the confluences of bio-, micro- and nano- technologies to create a low-cost non-invasive intelligent diagnosis system.

This platform will be developed in a modular format, which will allow each module to be developed and exploited individually. The modules will subsequently be integrated to facilitate the desired application. Advances in data communications, molecular biology and biosensor technology, with the integration of nanostructured functional components in macro and microsystems, will facilitate the realisation of a minimally invasive generic platform, which is capable of multi-parametric monitoring and will be interoperable with electronic medical records.

The advantages of integrated biosensor systems include their ease of use, their sensitivity, their inherent selectivity (preventing problems due to interfering substances), their versatility (allowing `in-field¿ use) and their cost effectiveness. Addressing the future health care requirement of an individualised theranostic approach, the specific application that will be demonstrated in this IP will be for the management, monitoring and diagnosis of coeliac disease, with the proposed technology contributing to significant advances in sensitivity and specificity of diagnosis. The technology platform developed, however, could be applied to a variety of clinical screening applications, such as cancer. The radical innovation proposed in this IP will result in a concrete prime deliverable of a technology platform of wide application and unquestionable socio-economic benefit, increasing European competitiveness whilst contributing considerably to the quality of life well being of the population.

For further information, please visit:
http://www.cdmedics.eu

Project co-ordinator:
Universitat Rovira i Virgili

Partners:

  • Institut für Mikrotechnik Mainz GmbH
  • Microfluidic ChipShop GmbH
  • Newcastle University
  • Intracom Telecom solutions
  • Clemens GmbH
  • Micro2Gen
  • Eurospital SpA
  • King's College London Business Ltd
  • INNO-TRAIN Diagnostik GmbH
  • TATAA Biocenter
  • MultiD Analyses AB
  • Finnish Red Cross Blood Service
  • Fondazione IRCCS Policlinico San Matteo
  • University Medical Centre Maribor
  • Valentia Technologies Limited
  • Association of European Coeliac Societies
  • Coeliac UK
  • Asociación de celíacos de Madrid
  • iXscient Ltd.
  • Newcastle upon Tyne Hospitals NHS Foundation Trust

Timetable: from 01/2008 – to 12/2011

Total cost: € 12.796.559

EC funding: € 9.500.000

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Open Call SC1-DTH-01-2019: Big Data and …

Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. Accurate risk assessment, availability of...

Cerner Selected for NHS Framework to Sup…

Integrated Care Systems (ICS) and Sustainability and Transformation Partnerships (STPs) aim to deliver the best possible quality of health and care, shift to value-based care and proactively improve outcomes for...

Brainlab and Magic Leap Partner in Digit…

Brainlab has announced a strategic development partnership with Florida-based Magic Leap, a developer of proprietary spatial computing solutions that help users enrich their real world experience by integrating digital content...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites...

Whole-Brain Connectome Maps Teach Artifi…

Medical University of South Carolina (MUSC) neurologists have developed a new method based on artificial intelligence that may eventually help both patients and doctors weigh the pros and cons of...

Oxehealth Secures World-First Accreditat…

The British Standards Institute (BSI) has accredited Oxehealth's vital signs measurement software as a Class IIa medical device in Europe. This is the first time that software enabling a digital...

MEDICA 2018: The Starting Block for Many…

12 - 15 November 2018, Düsseldorf, Germany. MEDICA, the world’s leading medical trade fair in Düsseldorf which attracts over 5,000 exhibitors from around 70 countries, is becoming an even bigger hotspot...

MEDICA 2018 Presents the Future of Medic…

12 - 15 November 2018, Düsseldorf, Germany. Artificial intelligence, Big Data or IoT (Internet of Things) - we would be hard pressed to find a sector that doesn’t have these terms...

Artificial Intelligence for Health: ITU …

The ITU Focus Group on 'AI for Health' (FG-AI4H), created in collaboration with the World Health Organization (WHO), has issued a Call for Proposals to identify compelling use cases of...

Siemens Healthineers and STORZ MEDICAL P…

On the occasion of the 70th annual congress of the German Society for Urology, DGU, Siemens Healthineers and STORZ MEDICAL have announced plans to enter into a sales partnership agreement...

Spinal Cord Stimulation, Physical Therap…

Spinal cord stimulation and physical therapy have helped a man paralyzed since 2013 regain his ability to stand and walk with assistance. The results, achieved in a research collaboration between...

Sandoz Healthcare Access Challenge #Sand…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global competition that invites entrepreneurs and innovators...